Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of paclitaxel polymeric micelles plus gemcitabine versus nab-paclitaxel plus gemcitabine in first-line metastatic pancreatic cancer
ChiCTR2400094707Phase 3Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and gemcitabine in pancreatic cancer (PC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-free survival. Started Jan 2025; status: recruiting.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2400094707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094707.